Trial Profile
A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Immune Markers After Minimum Maintenance Dose
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2022
Price :
$35
*
At a glance
- Drugs Food allergy immunotherapies (Primary) ; Omalizumab (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- 11 Jan 2022 Primary endpoint (Change in allergen-specific serum IgG4 and IgE) has not been met, according to Results published in the Allergy.
- 11 Jan 2022 Results published in the Allergy
- 16 Mar 2020 Results presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology